Strategies for avoiding neglect of opportunity costs by decision-makers

Jonathan Karnon*, Andrew Partington, Hossein Afzali

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

Abstract

Cost-effectiveness thresholds represent decision-makers’ maximum monetary valuation of a unit of outcome (typically a quality-adjusted life-year; QALY) in the context of decisions regarding the public funding of health technologies. If a technology is expected to generate additional QALYs at an incremental cost lower than the threshold, the technology is deemed to be cost effective. In this issue of Applied Health Economics and Health Policy, Lomas and colleagues note that the (policy) threshold used by the National Institute of Health and Care Excellence (NICE) is discrepant from the empirically estimated opportunity costs of the decisions made by NICE [1]. Here, we first confirm the relevance of empirical estimates of opportunity costs to informing the value of cost-effectiveness thresholds in different settings, and then build on Lomas et al.’s suggested strategy to avoid the neglect of empirical estimates of opportunity costs by decision-makers.

Original languageEnglish
Number of pages3
JournalApplied Health Economics and Health Policy
DOIs
Publication statusE-pub ahead of print - 1 Sep 2021

Fingerprint

Dive into the research topics of 'Strategies for avoiding neglect of opportunity costs by decision-makers'. Together they form a unique fingerprint.

Cite this